Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Tyra disappoints investors with bladder cancer data

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 9 September →